CILOSTAZOL AND PROTEASE INHIBITORS
Erythromycin increases the maximum plasma level and AUC of cilostazol by 47% and 73%, respectively. Other drugs that inhibit CYP3A4 (e.g. the protease inhibitors) would be expected to have a similar effect.
In view of these effects the US manufacturers suggest halving the dose of cilostazol in the presence of CYP3A4 inhibitors such as erythromycin. However, the UK manufacturers contraindicate CYP3A4 inhibitors, and they specifically name the protease inhibitors.
In view of these effects the US manufacturers suggest halving the dose of cilostazol in the presence of CYP3A4 inhibitors such as erythromycin. However, the UK manufacturers contraindicate CYP3A4 inhibitors, and they specifically name the protease inhibitors.